F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is well established as the imaging technique of choice for the assessment of patients with
Hodgkin lymphoma (HL) and the majority of non-Hodgkin lymphomas (NHLs), [1] [2] [3] [4] [5] [6] whole-body magnetic resonance imaging (MRI) has been proposed as an alternative to 18 F-FDG PET/CT, in particular if MR diffusion-weighted imaging (DWI) is part of the protocol. [7] [8] [9] [10] [11] [12] [13] At present, PET/CT is generally regarded as moderately superior to MRI with DWI, especially for nodal staging (partly due to motion artifacts that may occur in the head and neck region as well as the mediastinum), whereas DWI is considered superior to some indolent NHL subtypes, such as extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT), which are frequently not FDG avid. 12, 13 Whole-body 18 F-FDG PET/MR has only recently been introduced into routine clinical imaging, [14] [15] [16] and thus, its role in diagnosing lymphoma is still largely unknown. 18 F-FDG PET/MR offers not only a combination of metabolic information (provided by 18 F-FDG PET) with high soft tissue contrast anatomic resolution (provided by morphological MRI), but also enables, through the use of DWI, an indirect assessment of cell density.
Only 3 studies have been published with regard to the value of 18 F-FDG PET/MR for assessing HL and NHL; as yet, one of them included only nodal lymphoma manifestations and did not include DWI at all 17 ; another study focused exclusively on therapy response and only applied DWI in 2 patients. 18 The most recent study included DWI, but only as a stand-alone technique, rather than as part of the 18 F-FDG PET/MR protocol. 19 Furthermore, none of these studies included a relevant number of lymphomas with variable FDG avidity, such as MALT lymphoma, even though, for instance, the latter is the third most common NHL subtype.
Thus, it was the aim of our study to directly and prospectively compare 18 F-FDG PET/MR, including DWI, to 18 F-FDG PET/CT, with regard to the assessment of nodal and extranodal involvement, in lymphoma patients, without restriction to FDG-avid subytpes.
MATERIALS AND METHODS

Patients and Study Design
Between January 2014 and April 2015, patients with histologically proven lymphoma (as verified by a reference pathologist who analyzed tissue samples obtained by biopsy or surgery, according to the current World Health Organization classification of hematological and lymphoid malignancies), who were referred to the local tertiary care center for pretherapeutic staging or follow-up, were invited to participate in this single-tracer injection, dual-modality study. The study was approved by the local institutional review board. Patients who gave written informed consent underwent 18 F-FDG PET/CT and, directly after it, 18 F-FDG PET/MR (see protocols below). Pregnancy, general contraindications to MRI (eg, claustrophobia, metal implants), elevated glucose levels (>150 mg/dL), and known adverse reactions to ionized contrast media were used as exclusion criteria.
Imaging Protocols
18
F-FDG PET/CT and 18 F-FDG PET/MR were performed consecutively on the same day, using only a single injection of 18 F-FDG for both examinations. 18 F-FDG PET/CT was generally performed first, covering the anatomy from the vertex to the upper thigh, using a 64-row multidetector hybrid PET/CT device (Biograph TruePoint 64; Siemens, Erlangen, Germany). For PET, this scanner offers an axial field of view (FOV) of 216 mm, a sensitivity of 7.6 cps/kBq, and a transaxial resolution of 4 to 5 mm. After patients had fasted for 5 hours, PET was performed 45 to 60 minutes after an intravenous administration of 300 MBq of 18 F-FDG, with 3 minutes/bed position, 4 iterations, 21 subsets, a 5-mm slice thickness, and a 168 Â 168 matrix, using the point-spread functionbased reconstruction algorithm TrueX. Venous-phase contrast-enhanced (CE) CT was used for attenuation correction and was obtained after the intravenous injection of 100 mL of a tri-iodinated, nonionic contrast medium at a rate of 2 mL/s; a tube voltage of 120 mA; a tube current of 230 kV; a collimation of 64 Â 0.6 mm; a 3-mm slice thickness with a 2-mm increment; and a 512 Â 512 matrix. Contrast-enhanced CTwas used instead of unenhanced CT because, as well demonstrated in the literature, the administration of contrast medium improves the evaluation of extranodal disease and better delineates lymph node stations. 20 18 F-FDG PET/MR, covering the same anatomy as the PET/CT, was performed directly after PET/CT, using an integrated, simultaneous, hybrid PET/MR device (Biograph mMR; Siemens, Erlangen, Germany) operating at 3 T, with high-performance gradient systems (45 mT/m) and a slew rate of 200 T/m/s, and equipped with a phasedarray body coil. For PET, the system offers an axial FOV of 256 mm, a sensitivity of 13.2 cps/kBq, and a transaxial resolution of 4.4 mm. Positron emission tomography was performed 100 to 150 minutes after the original tracer administration, with 5 minutes/bed position, 3 iterations, 21 subsets, a 4.2-mm slice thickness, and a 172 Â 172 matrix, using the point-spread function-based reconstruction algorithm High Definition-PET. An axial, 2-point Dixon, 3-dimensional, volumeinterpolated, T1-weighted breath-hold MR sequence (VIBE) was acquired for attenuation correction and for anatomic correlation, using the following parameters: repetition time (TR)/echo times (TE), 4.02/1.23, 2.46 milliseconds; 1 average, 2 echoes; a 10-degree flip angle; a 320 Â 175 matrix with a 430 Â 309 mm FOV; and a 3-mm slice thickness with 0.6-mm gap. A coronal T2-weighted half-fourier acquisition singleshot turbo spin-echo (HASTE) was performed applying the following parameters: TR/TE, 1400/121 milliseconds; a 108-degree flip angle; a 256 Â 256 matrix with a 380 Â 380 mm FOV; and a 6-mm slice thickness with a 1.2-mm gap. A single-shot, echo planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with the following parameters: b-values, 50 and 800; TR/TE, 6800/63 milliseconds; 6 averages and 1 echo; a 180-degree flip angle; a 168 Â 104 matrix with a 440 Â 340 mm FOV; and a 6-mm slice thickness with a 1.2-mm gap. The total scanning time for entire PET/MR examination was~120 minutes, including~15 to 20 minutes for the DWI sequence.
Image Analysis
The 14 nodal regions defined at the Rye symposium 21 and the following 12 extranodal regions were evaluated: Waldeyer ring, lungs, liver, spleen, stomach, small intestine, large intestine, right kidney, left kidney, bones, soft tissues (skin/fat/muscle), and other organs/tissues (eg, salivary glands). A patient was rated positive if at least 1 region was positive. Staging, according to the modified Ann Arbor system (stage I to IV), 3, 22 was performed for all pretherapeutic staging examinations. In addition, stage 0 was reported for cases rated as negative (ie, negative at imaging and/or at the reference standard). A boardcertified radiologist and a board-certified nuclear medicine physician, who were blinded to the clinical and histological information, performed all analyses in consensus.
F-FDG PET/CT
Positron emission tomography/CT was rated as positive if at least one of the nodal or extranodal regions demonstrated 1 or more focally increased tracer accumulations relative to the surrounding tissues or mediastinal blood pool activity (for staging) or to the liver (for restaging).
2 Contrast-enhanced CT was used for anatomical correlation and (in case of lymph nodes) morphological verification. In accordance with the Lugano classification, 2 the spleen and liver were also rated as positive if there was a diffusely increased FDG uptake.
In the absence of abnormal 18 F-FDG PET findings, lymph nodes were also rated as positive, using CE-CT, if they met the size criteria defined by the International Working Group 20 : a long-axis diameter of more than 1.5 cm or a long-axis and short-axis diameter of more than 1 cm each. 20 The spleen was rated as positive if its vertical diameter was greater than 13 cm. 2 No other size criteria were applied for extranodal regions, and all noncystic, nonfatty lesions (ie, Hounsfield units greater than 20) on CE-CT were rated as positive for lymphoma, unless they showed well-established benign features (eg, nodular peripheral enhancement in hemangiomas of the liver). F-FDG PET/MR DWI (ie, PET/MR with DWI), PET criteria for lymphoma involvement were identical to those used for 18 F-FDG PET/MR without DWI (see above). In the absence of pathological PET findings, however, nodal and extranodal regions were also rated as positive if there was a lesion with restricted diffusion, that is, with a high signal on b800 DWI and a low signal on the corresponding apparent diffusion coefficient (ADC) map. 23 Because false-positive findings in lymph nodes have been previously reported with DWI, 24 only lymph nodes with restricted diffusion that had a long axis diameter of more than 1 cm were rated as positive. The spleen was rated as positive if the vertical diameter was greater than 13 cm, 2 as assessed on coronal T2 HASTE MRI, or if DWI showed evident signal inhomogeneity or well-circumscribed lesions with restricted diffusion. 25, 26 Bone and bone marrow were rated as positive if, in addition to a focal or diffuse diffusion restriction, there was also a low signal on T1-weighted MRI. 12 
Quantitative Analysis
For each nodal and extranodal region rated as positive, the lesion demonstrating the largest diameter was selected, and the maximum and mean standardized uptake value (SUV max and SUV mean ), assessed independently on 18 F-FDG PET/CT and 18 F-FDG PET/MR, as well as the minimum and the mean ADC (Â10 −6 mm 2 /s), were measured. For the SUV measurements, isocontour volumes of interest that included all voxels more than 50% of the SUV max of each lesion, were used. However, ADC measurements were based on regions of interest that were manually defined 27 on the ADC map section that showed the maximum transverse diameter of a lesion. All quantitative measurements were performed by the same rater.
Reference Standard and Statistical Analysis
For staging, histology was used as the main reference standard and was required for all extranodal lymphoma manifestations. For suspected lymph node involvement, histological verification in at least a single nodal region was required. In case of involvement of multiple nodal regions, positive findings on both 18 F-FDG PET and DWI were required to verify each non-histologically proven region (combined reference standard). The combined reference standard was also used for posttreatment restaging, unless rebiopsy was performed-in the latter case, the main reference standard was used on a per-region basis.
To determine the diagnostic values of F-FDG PET/CT, examination-based sensitivity, specificity, and accuracy, as well as their 95% confidence intervals (CIs), were calculated. κ Coefficients were used to assess the region-based agreement and the agreement for the modified Ann Arbor Staging system. Spearman correlation coefficients (r) were used to assess the relationship between SUVs and ADCs. The specified level of significance was P ≤ 0.05 for all tests. All statistical tests were performed using IBM SPSS Statistics 21.0 (IBM Corp, Armonk, NY). F-FDG PET/MR DWI were 82.1%, 85.7%, and 100%, respectively, whereas specificities were 100% for all 3 techniques, and accuracies were 87.5%, 90%, and 100%, respectively ( Table 2) . 18 F-FDG PET/CT was false negative in 5 of 40 examinations (ie, 4 MALT lymphoma patients, one of them scanned for staging and restaging) (Fig. 1) . 
RESULTS
Thirty
Ann Arbor Staging
Region-Based Agreement
Overall, 1036 of 1040 regions were available for comparative analysis; the remaining 4, as aforementioned, were excluded due to artifacts on (Table 3) .
Quantitative Analysis
One hundred five lesions were included in the quantitative analysis. Mean ± SD SUV max and SUV mean values were 9.07 ± 5.87 and 5.48 ± 3.49 on 
DISCUSSION
The results of our study-which is, to date, the largest of its kind, the first that also included a relevant number of lymphomas with variable FDG avidity, and also the first that specifically evaluated the effect of including DWI in the PET/MR protocol-clearly suggest that 18 F-FDG PET/CT and 18 F-FDG PET/MR generally show a comparable performance in patients with lymphoma. Thus, our results are in good accordance with the few previous studies that reported a similar diagnostic performance of the 2 techniques [17] [18] [19] in lymphoma patients, and also in general accordance with the results of previous comparative studies in other types of cancer. 15, [28] [29] [30] As mentioned previously, the present study did not, a priori, exclude certain lymphoma subytpes, such as MALT lymphomas, which frequently show low, or no, FDG uptake. This strategy for inclusion/ exclusion of patients was chosen because, in clinical practice, staging by means of imaging tests is sometimes performed before surgery/ biopsy or before histologic workup of the tissue blocks, and thus, patients with lymphomas with variable FDG avidity (eg, MALT lymphoma, splenic MZL, small lymphocytic lymphoma/chronic lymphocytic leukemia, enteropathy-associated T-cell lymphoma, and primary cutaneous anaplastic large T-cell lymphoma) may still routinely undergo study that compared (stand-alone) DWI-MRI to 18 F-FDG PET/CT, as well as CE-CT, reported a superiority of DWI-MRI in indolent NHLs with variable FDG avidity. 12 However, the effect of including DWI in the 18 F-FDG PET/MR protocol would almost certainly not be as pronounced in a typical lymphoma population as it was in our study: 15 of 34 of our patients were diagnosed with MALT lymphoma, although this lymphoma subtype, while the third most common NHL, is normally responsible for just 7% to 8% of all NHLs. 31 By contrast, only 4 of 34 patients were diagnosed with the 2 most common types of NHL: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This highly atypical distribution of lymphoma subtypes within our sample is clearly due to the fact that one of the referring oncologists is an internationally recognized specialist for extranodal lymphomas, with a special focus on the MALT subtype.
With regard to region-based agreement, we noticed some discrepancies between the F-FDG PET/CT, we hypothesize that the later time point used for the PET acquisition may be responsible for these findings. Indeed, delayed time point 18 F-FDG PET has already been demonstrated to improve the detection of colorectal and breast cancers, 32, 33 as well as metastatic lymph nodes from lung and esophageal cancer. 34, 35 A single study by Shinya et al 35 demonstrated that dual time point 18 F-FDG PET has the potential to provide a higher accuracy for the detection of aggressive lymphomas. Together with the aforementioned observation by Heacock et al, our findings suggest that the latter may also be true for indolent lymphomas. However, this topic was not within the scope of the present study, and thus, further studies are required to investigate this topic in detail.
With regard to quantitative measurements, several studies have already suggested an inverse correlation between SUV and ADC values. [36] [37] [38] SUV and ADC values are tumor biomarkers reflecting, respectively, tumor glucose metabolism (correlating with tumor grade) and tissue cellularity [39] [40] [41] (clinically applied to differentiate benign from malignant tumors and to assess tumor grade, delineate tumor extent, and predict survival). In our population, we observed substantial correlations of SUV max and SUV mean values between 18 F-FDG PET/ MR and 18 F-FDG PET/CT, as also reported also by Heacock et al. 19 Recently, Punwani et al 42 demonstrated a significant negative correlation between ADC and SUV values, whereas in our study, the only significant correlation between these quantitative parameters was a weak negative correlation between SUV mean and ADC mean . This discrepancy may be due the fact that Punwani et al analyzed only a single lymphoma subtype (ie, Hodgkin). Notably, Heacock et al 19 and de Jong et al, 43 in their mixed lymphoma populations, also did not observe significant correlations between SUVand ADC values, and neither did Wu et al, 37 in patients with DLBCL. Thus, there seems to be no general relationship between glucose metabolism, as assessed by 18 F-FDG PET, and cell density, as assessed by DWI, across the entire spectrum of histological lymphoma subtypes.
The aforementioned, atypical distribution of lymphoma subtypes represents the main limitation of our study. However, combined with the results of previous, as well as future studies in patient populations with more typical lymphoma subtype distributions (ie, higher percentages of patients with HL, DLBCL, and follicular lymphoma), it may provide a wellrounded overview of the performance of 18 F-FDG PET/MR, compared with that of 18 F-FDG PET/CT, in this group of cancers. The fact that, on 18 F-FDG PET/MR DWI, we rated lesions as pathologic if they were positive on PET or DWI (ie, no agreement between the 2 was considered necessary) may be regarded as prone to overestimating the diagnostic performance of 18 F-FDG PET/MR DWI. However, we believe that, in general, the main strength of PET/MR lies in its multiparametric capabilities, and because the underlying information derived from 18 F-FDG PET (direct visualization of glucose metabolism at the cellular level) is quite different from that of DWI (indirect assessment of cell density), we believe that our evaluation strategy is justified.
In conclusion, the results of our study indicate that 18 F-FDG PET/MR is practically equal to 18 F-FDG PET/CT for the assessment of HL and aggressive NHLs, regardless of whether or not DWI is included in the protocol. In indolent NHLs, which include those with a variable FDG avidity, the addition of DWI improves the sensitivity and accuracy of 
